Connectomic biotyping of schizophrenia patients

精神分裂症患者的连接组生物分型

• 批准号: nhmrc : GNT1142801
• 负责人: A/Pr Andrew Zalesky
• 金额: $ 26.51万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/connectomic-biotyping-schizophrenia-patients/1348478
• 关键词: Connectomic; biotyping; schizophrenia; patients

Patients with schizophrenia differ widely in their symptoms, long-term outcome and response to medication. However, most patients are treated with the same medications and interventions. This study aims to better facilitate the targeting of novel treatments to groups of patients (biotypes) that are likely to benefit most from a treatment. Groups of patients that share distinct patterns of deficits in brain connectivity will be delineated using state-of-the-art white matter imaging techniques.

精神分裂症患者的症状、长期结果和对药物的反应差异很大。然而，大多数患者接受相同的药物和干预措施治疗。这项研究旨在更好地促进新疗法针对可能从治疗中受益最大的患者群体（生物型）。将使用最先进的白质成像技术来描绘具有不同大脑连接缺陷模式的患者群体。